SPONSOR
Shanghai Hengrui Pharmaceutical Co., Ltd.
Total Trials
8
Recruiting
8
Phases
Phase 2, Phase 1, Phase 2, Phase 1
Conditions studied: Advanced Gynecological MalignancyAdvanced or Metastatic Esophageal CancerAdvanced Solid TumorsMultiple MyelomaHigh-risk NMIBCCLDN18.2-positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd. is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Advanced Gynecological Malignancy, Advanced or Metastatic Esophageal Cancer, Advanced Solid Tumors, Multiple Myeloma.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Hengrui Pharmaceutical Co., Ltd.
How many clinical trials has Shanghai Hengrui Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd., of which 8 are actively recruiting participants. These trials cover conditions including Advanced Gynecological Malignancy, Advanced or Metastatic Esophageal Cancer, Advanced Solid Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Hengrui Pharmaceutical Co., Ltd. research focus on?
Shanghai Hengrui Pharmaceutical Co., Ltd. clinical trials span Advanced Gynecological Malignancy, Advanced or Metastatic Esophageal Cancer, Advanced Solid Tumors, Multiple Myeloma, High-risk NMIBC, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Hengrui Pharmaceutical Co., Ltd. clinical trial?
To participate in a Shanghai Hengrui Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Hengrui Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06654440 Phase 2
Recruiting
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Advanced Gynecological Malignancy
NCT06474468 Phase 1, Phase 2
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Advanced or Metastatic Esophageal Cancer
NCT06474455 Phase 1, Phase 2
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Advanced Solid Tumors
NCT07490613 Phase 1
Recruiting
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Multiple Myeloma
NCT05410730 Phase 1, Phase 2
Recruiting
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
High-risk NMIBC
NCT06895928 Phase 2
Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Advanced Solid Tumors
NCT06605222 Phase 1, Phase 2
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Advanced Solid Tumors
NCT06350006 Phase 1
Recruiting
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
CLDN18.2-positive Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology